Oleanolic acid increases the anticancer potency of doxorubicin in pancreatic cancer cells

Abstract Combination therapy is a novel cancer therapy approach that combines two or more chemotherapy drugs. This treatment modality enhances the efficacy of chemotherapy by targeting key pathways in an additive or synergistic manner. Therefore, we investigated the efficacy of combination therapy by widely used chemotherapy drug doxorubicin (DOX) and oleanolic acid (OA) to induction of apoptosis for pancreatic cancer (PC) therapy. The effects of DOX, OA, and their combination (DOX‐OA) were investigated on proliferation and viability of PC cell line (PANC‐1) by MTT assay. Moreover, migration and invasion of the cancer cells were evaluated by trans‐well migration assay and wound healing assay. Flow cytometry and DAPI (4′,6‐diamidino‐2‐phenylindole) staining were employed to investigate apoptosis quantification and qualification of the treated cancer cells. Finally, mRNA expression of apoptosis‐related genes was assessed by quantitative real‐time polymerase chain reaction. Our results demonstrated that the proliferation and metastasis potential of PC cells significantly decreased after treatment by DOX, OA, and DOX‐OA. Moreover, we observed an increase in apoptosis percentage in the treated cancer cells. The apoptosis‐related gene expression was modified to increase the apoptosis rate in all of the treatment groups. However, the anticancer potency of DOX‐OA combination was significantly more than that of DOX and OA treatments alone. Our study suggested that DOX‐OA combination exerts more profound anticancer effects against PC cell lines than DOX or OA monotherapy. This approach may increase the efficiency of chemotherapy and reduce unintended side effects by lowering the prescribed dose of DOX.